Literature DB >> 11090974

Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin.

Y Hosaka1, T Higuchi, M Tsumagari, H Ishii.   

Abstract

Thrombomodulin (TM) is an anticoagulant molecule expressed on the endothelial cell surface and soluble TM antigen, which is present in human plasma and urine, represents the products of limited proteolytic cleavage of cell-surface TM. Recently, it was demonstrated that TM is also expressed on the surface of several tumor cells and the expression level of TM negatively correlated with malignancy in cancer. We investigated the effect of soluble TM isolated from human urine (uTM) on the invasion and metastasis of murine melanoma cells (B16F10 cells) through a reconstituted basement membrane (Matrigel) and in a murine model of experimental lung metastasis. Matrigel reconstituted with uTM inhibited the invasion of B16F10 cells in a dose-dependent manner in a range from 10 to 1000 ng/ml uTM as compared with the control Matrigel without uTM. The inhibitory action of uTM was not altered in the presence of an excess amount of hirudin, an inhibitor of thrombin proteolytic activity, but abolished in the presence of anti-human TM IgG. Matrigel reconstituted with thrombin (1 NIH unit/ml) enhanced the invasion level of cells by 1.5-fold relative to the control Matrigel without thrombin. The thrombin-enhanced invasion of B16F10 cells was repressed by addition of hirudin (10 units/ml) or uTM (100 ng/ml) into the Matrigel. Matrigel reconstituted with hirudin (10 units/ml) and uTM (100 ng/ml) additionally accelerated the inhibitory activity of hirudin or uTM on the thrombin-enhanced invasion of B16F10 cells. Moreover, metastatic colonies formed in the lungs of mice injected intravenously with B16F10 cells were significantly reduced by injection of uTM once a day up to 2 days after co-injection of uTM with the cells. These results suggested that Matrigel reconstituted with uTM inhibited the invasion of B16F10 cells in vitro through a thrombin-independent mechanism and the injection of uTM suppressed experimental lung metastasis of the cells in mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090974     DOI: 10.1016/s0304-3835(00)00617-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.

Authors:  Joseph S Palumbo; Kathryn E Talmage; Jessica V Massari; Christine M La Jeunesse; Matthew J Flick; Keith W Kombrinck; Zhiwei Hu; Kelley A Barney; Jay L Degen
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

Review 2.  C-type lectin family XIV members and angiogenesis.

Authors:  Supriya Borah; Dileep Vasudevan; Rajeeb K Swain
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

3.  Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.

Authors:  Netanel A Horowitz; Elizabeth A Blevins; Whitney M Miller; Ashley R Perry; Kathryn E Talmage; Eric S Mullins; Matthew J Flick; Karla C S Queiroz; Kun Shi; C Arnold Spek; Edward M Conway; Brett P Monia; Hartmut Weiler; Jay L Degen; Joseph S Palumbo
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

4.  Thrombomodulin modulates cell migration in human melanoma cell lines.

Authors:  Andreia da Silva de Oliveira; Likiu Yang; Juliana Echevarria-Lima; Robson Q Monteiro; Alireza R Rezaie
Journal:  Melanoma Res       Date:  2014-02       Impact factor: 3.599

5.  Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays.

Authors:  N J W de Wit; J Rijntjes; J H S Diepstra; T H van Kuppevelt; U H Weidle; D J Ruiter; G N P van Muijen
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

6.  Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival.

Authors:  A M Hanly; M Redmond; D C Winter; S Brophy; J M Deasy; D J Bouchier-Hayes; E W Kay
Journal:  Br J Cancer       Date:  2006-05-08       Impact factor: 7.640

7.  The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways.

Authors:  Edward M Conway; Marlies Van de Wouwer; Saskia Pollefeyt; Kerstin Jurk; Hugo Van Aken; Astrid De Vriese; Jeffrey I Weitz; Hartmut Weiler; Peter W Hellings; Paul Schaeffer; Jean-Marc Herbert; Désiré Collen; Gregor Theilmeier
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

8.  Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.

Authors:  Zainab A Bazzi; Danielle Lanoue; Mouhanned El-Youssef; Rocco Romagnuolo; Janice Tubman; Dora Cavallo-Medved; Lisa A Porter; Michael B Boffa
Journal:  BMC Cancer       Date:  2016-05-24       Impact factor: 4.430

Review 9.  Thrombomodulin as a Physiological Modulator of Intravascular Injury.

Authors:  Kanako Watanabe-Kusunoki; Daigo Nakazawa; Akihiro Ishizu; Tatsuya Atsumi
Journal:  Front Immunol       Date:  2020-09-16       Impact factor: 7.561

10.  Prognostic Significance of Thrombomodulin mRNA in High-Grade Soft Tissue Sarcomas after 10 years.

Authors:  Kunihiro Asanuma; Tomoki Nakamura; Yumiko Asanuma; Takayuki Okamoto; Takuya Kakimoto; Yuki Yada; Tomohito Hagi; Kouji Kita; Koichi Nakamura; Akihiko Matsumine; Akihiro Sudo
Journal:  Orthop Surg       Date:  2020-10-04       Impact factor: 2.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.